Vesalius Biocapital I

Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, founded in 2016. The company specializes in developing rapid tests that assess the immune system to address significant clinical and public health challenges. Its primary focus is on creating diagnostics for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix employs proprietary machine-learning algorithms to analyze immune responses, producing clinically actionable results that support healthcare providers, particularly in emergency medicine, in making informed diagnostic decisions. Additionally, the company is building a diagnostics pipeline that includes tests for tropical infections, autoimmune diseases, transplant rejection, and various other conditions.

Caresyntax Inc. is a Boston-based company that provides a digital surgery platform to enhance surgical performance in hospitals and ambulatory surgical centers. Founded in 1991, it leverages data from over 1,600 hospitals globally to deliver insights that improve patient outcomes and operational efficiency. The platform integrates various data sources, including video, audio, clinical, and operational data, enabling real-time analysis and decision-making during surgeries. Caresyntax offers solutions such as qvident, a performance management software, and PRIME365, a comprehensive integration platform that consolidates surgical data and content. With a focus on automating workflows and reducing surgical variability, Caresyntax supports over 4,000 operating rooms and has facilitated millions of surgical procedures worldwide. The company’s HIPAA-compliant software can be deployed on-premise, in the cloud, or in a hybrid format, making it adaptable to diverse healthcare environments.

CatalYm GmbH, founded in 2016 and based in Munich, Germany, is a biotechnology company focused on developing innovative immunotherapies for cancer patients. The company has identified GDF-15 as a key regulator of the immune system within the tumor microenvironment. By neutralizing GDF-15, CatalYm aims to enhance the immune response against solid tumors, potentially leading to meaningful clinical outcomes. Its CTL-002 program is designed to demonstrate clinical proof-of-concept across multiple solid tumor indications, offering the prospect of expanding treatment options for cancer patients. Through its approach, CatalYm seeks to transform the tumor microenvironment, making tumors more accessible to the immune system and improving both survival rates and quality of life for patients.

HepaRegeniX GmbH, founded in 2016 and based in Ulm, Germany, focuses on developing innovative drugs for acute and chronic liver diseases. The company's therapeutic approach is centered on a proprietary molecular target known as mitogen-activated protein kinase 4 (MKK4), identified as a crucial regulator of liver regeneration through research by Professor Lars Zender and his team at the University Hospital Tübingen. HepaRegeniX aims to create small-molecule inhibitors of MKK4 that can enhance the regenerative capacity of hepatocytes, even in severely diseased livers. This research has significant implications for treating various liver disorders, including nonalcoholic steatohepatitis.

inHEART specializes in advanced precision medicine for cardiology, utilizing artificial intelligence to enhance the care of patients with cardiac diseases. The company develops innovative software solutions that create a digital twin of the heart, transforming preoperative medical images into a detailed model. This technology aids cardiologists in diagnosing, planning, and navigating procedures related to heart rhythm disorders, such as arrhythmias and heart failure. By bridging the gap between radiology and cardiology, inHEART aims to improve treatment personalization and reduce procedure durations and failure rates, ultimately advancing patient care in the field of cardiovascular medicine.

Cognivia specializes in creating analytical tools that enhance and expedite the clinical development of new medicines. The company focuses on developing predictive techniques that improve the clinical evaluation of drugs and other therapeutics. By addressing key sources of variability in clinical trial data, Cognivia enables clients to better identify and manage challenges, ultimately leading to more efficient and effective clinical trials.

Tonic App S.A. is a technology company based in Porto, Portugal, that has developed a mobile application designed to enhance communication and collaboration among medical professionals. The application supports doctors by enabling messaging, sharing, and archiving of patient cases, as well as facilitating expert consultations and networking opportunities. It serves various stakeholders in the healthcare sector, including hospitals, pharmaceutical companies, and medical associations, to connect medical doctors with their peers and relevant communities. Additionally, the application provides access to essential medical content, allows for the coordination of urgent procedures, and enables discussions on clinical cases. With features like video consultations, prescription tools, and clinical decision support resources, Tonic App aims to improve the efficiency of clinical practices and ultimately enhance patient outcomes. Established in 2016, the company is recognized for its commitment to quality and safety in its clinical algorithms.

Memo Therapeutics AG, based in Basel, Switzerland, specializes in innovative antibody discovery and immune repertoire analysis. The company utilizes its proprietary MemoMAB platform, which generates a recombinant in vitro copy of an individual's B cell or antibody repertoire, creating extensive libraries that represent unique immune responses. These libraries are expected to contain a vast array of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics applies this technology in its own antibody lead discovery programs and partners with other entities to enhance research and development in the fields of viral infections and cancer. Through its advancements, Memo Therapeutics aims to significantly improve therapeutic options for patients.

CatalYm GmbH, founded in 2016 and based in Munich, Germany, is a biotechnology company focused on developing innovative immunotherapies for cancer patients. The company has identified GDF-15 as a key regulator of the immune system within the tumor microenvironment. By neutralizing GDF-15, CatalYm aims to enhance the immune response against solid tumors, potentially leading to meaningful clinical outcomes. Its CTL-002 program is designed to demonstrate clinical proof-of-concept across multiple solid tumor indications, offering the prospect of expanding treatment options for cancer patients. Through its approach, CatalYm seeks to transform the tumor microenvironment, making tumors more accessible to the immune system and improving both survival rates and quality of life for patients.

Scenic Biotech is a biotechnology company focused on developing innovative genomics and immunotherapy technologies aimed at addressing severe diseases, including cancer and rare genetic disorders. The company's approach involves identifying genetic suppressors, which are genes that can counteract the effects of disease-causing mutations, thus serving as new drug targets. By leveraging its advanced technology, Scenic Biotech enables scientists to rapidly identify and validate these novel drug targets, facilitating the development of disease-modifying therapeutics. This targeted strategy not only enhances the understanding of genetic influences on diseases but also aims to improve treatment outcomes for affected patients.

Memo Therapeutics AG, based in Basel, Switzerland, specializes in innovative antibody discovery and immune repertoire analysis. The company utilizes its proprietary MemoMAB platform, which generates a recombinant in vitro copy of an individual's B cell or antibody repertoire, creating extensive libraries that represent unique immune responses. These libraries are expected to contain a vast array of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics applies this technology in its own antibody lead discovery programs and partners with other entities to enhance research and development in the fields of viral infections and cancer. Through its advancements, Memo Therapeutics aims to significantly improve therapeutic options for patients.

Rejuvenate Biomed is a biomedical company focused on researching the biology of aging to develop safe and effective drugs aimed at maintaining and restoring cellular resilience. By leveraging large datasets and employing network biology, the company seeks to identify synergistic drug combinations that can delay the onset of age-related diseases. This approach allows medical researchers to target and balance the core biological processes that contribute to functional decline associated with aging, ultimately improving responses to age-related health challenges.

Caresyntax Inc. is a Boston-based company that provides a digital surgery platform to enhance surgical performance in hospitals and ambulatory surgical centers. Founded in 1991, it leverages data from over 1,600 hospitals globally to deliver insights that improve patient outcomes and operational efficiency. The platform integrates various data sources, including video, audio, clinical, and operational data, enabling real-time analysis and decision-making during surgeries. Caresyntax offers solutions such as qvident, a performance management software, and PRIME365, a comprehensive integration platform that consolidates surgical data and content. With a focus on automating workflows and reducing surgical variability, Caresyntax supports over 4,000 operating rooms and has facilitated millions of surgical procedures worldwide. The company’s HIPAA-compliant software can be deployed on-premise, in the cloud, or in a hybrid format, making it adaptable to diverse healthcare environments.

Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological capabilities. Its lead product candidate, TPM203, is currently undergoing clinical testing for pemphigus vulgaris, an orphan disease. Additional programs are being developed for conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. Topas Therapeutics has established research and collaboration agreements with notable partners, including Eli Lilly and Company and Boehringer Ingelheim, to advance its innovative approaches to immune tolerance. The company aims to address significant unmet medical needs by promoting immune tolerance to blood-borne antigens.

Rejuvenate Biomed is a biomedical company focused on researching the biology of aging to develop safe and effective drugs aimed at maintaining and restoring cellular resilience. By leveraging large datasets and employing network biology, the company seeks to identify synergistic drug combinations that can delay the onset of age-related diseases. This approach allows medical researchers to target and balance the core biological processes that contribute to functional decline associated with aging, ultimately improving responses to age-related health challenges.

Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.

CatalYm GmbH, founded in 2016 and based in Munich, Germany, is a biotechnology company focused on developing innovative immunotherapies for cancer patients. The company has identified GDF-15 as a key regulator of the immune system within the tumor microenvironment. By neutralizing GDF-15, CatalYm aims to enhance the immune response against solid tumors, potentially leading to meaningful clinical outcomes. Its CTL-002 program is designed to demonstrate clinical proof-of-concept across multiple solid tumor indications, offering the prospect of expanding treatment options for cancer patients. Through its approach, CatalYm seeks to transform the tumor microenvironment, making tumors more accessible to the immune system and improving both survival rates and quality of life for patients.

Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological capabilities. Its lead product candidate, TPM203, is currently undergoing clinical testing for pemphigus vulgaris, an orphan disease. Additional programs are being developed for conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. Topas Therapeutics has established research and collaboration agreements with notable partners, including Eli Lilly and Company and Boehringer Ingelheim, to advance its innovative approaches to immune tolerance. The company aims to address significant unmet medical needs by promoting immune tolerance to blood-borne antigens.

Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.

OncoDNA, established by experts with over six decades of combined experience in medical diagnostics, specializes in precision medicine for cancer and genetic diseases. The company offers clinical guidance and real-time monitoring for late-stage cancer patients, aiding clinicians, researchers, and biopharma companies in advancing cancer and genetic disease treatments.

Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of custom orthopedic aids, including orthoses and prostheses. The company empowers orthopedic and prosthetic (O&P) professionals through its Mecuris Solution Platform, which integrates digital technology and 3D printing. This platform allows for the co-creation of individualized O&P products by utilizing patient data and scans to semi-automatically generate custom 3D designs. These designs can be printed locally, ensuring a tailored fit and reducing production times by up to 75%. Mecuris aims to enhance the lives of wearers by providing quick, personalized solutions that meet their specific needs.

Tonic App S.A. is a technology company based in Porto, Portugal, that has developed a mobile application designed to enhance communication and collaboration among medical professionals. The application supports doctors by enabling messaging, sharing, and archiving of patient cases, as well as facilitating expert consultations and networking opportunities. It serves various stakeholders in the healthcare sector, including hospitals, pharmaceutical companies, and medical associations, to connect medical doctors with their peers and relevant communities. Additionally, the application provides access to essential medical content, allows for the coordination of urgent procedures, and enables discussions on clinical cases. With features like video consultations, prescription tools, and clinical decision support resources, Tonic App aims to improve the efficiency of clinical practices and ultimately enhance patient outcomes. Established in 2016, the company is recognized for its commitment to quality and safety in its clinical algorithms.

Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company focuses on the tissue-specific regulation of sex hormone effects to address various urological and endocrinological diseases. Its key products include Fispemifene, a selective estrogen receptor modulator designed to treat symptoms of low testosterone in men, and a 17HSD1-inhibitor targeting endometriosis. Forendo Pharma aims to enhance treatment options for both men's and women's health by developing innovative therapies that address unmet medical needs in gynecological conditions, such as endometriosis and polycystic ovarian syndrome.

DEARhealth, Inc. is a health technology company based in Beverly Hills, California, that specializes in developing a software-as-a-service (SaaS) healthcare management platform tailored for medical providers and health insurers. Founded in 2013, the company focuses on value-based healthcare solutions aimed at enhancing the health outcomes and experiences of chronically ill patients while simultaneously reducing associated costs. Utilizing advanced data analytics, DEARhealth's platform facilitates coordinated care pathways, streamlines provider workflows, and supports organizational decision-making. The technology is specifically designed for the management of complex and costly diseases, enabling healthcare professionals to optimize care and improve measurable patient outcomes.

Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of custom orthopedic aids, including orthoses and prostheses. The company empowers orthopedic and prosthetic (O&P) professionals through its Mecuris Solution Platform, which integrates digital technology and 3D printing. This platform allows for the co-creation of individualized O&P products by utilizing patient data and scans to semi-automatically generate custom 3D designs. These designs can be printed locally, ensuring a tailored fit and reducing production times by up to 75%. Mecuris aims to enhance the lives of wearers by providing quick, personalized solutions that meet their specific needs.

OMEICOS Therapeutics GmbH is a Berlin-based company founded in 2013 that specializes in developing novel therapeutics for cardiovascular diseases and other health conditions. The company focuses on small molecule therapies derived from natural metabolites of omega-3 fatty acids, which exhibit a unique mode of action. These substances activate an endogenous cardio-protective signaling pathway, providing both anti-arrhythmic effects and curative benefits by stabilizing heart rhythm and preventing electrical and structural remodeling of the heart. In addition to cardiovascular applications, OMEICOS also explores treatments for inflammatory and ophthalmic diseases, aiming to deliver safe and effective therapeutic options for various medical indications.

Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company focuses on the tissue-specific regulation of sex hormone effects to address various urological and endocrinological diseases. Its key products include Fispemifene, a selective estrogen receptor modulator designed to treat symptoms of low testosterone in men, and a 17HSD1-inhibitor targeting endometriosis. Forendo Pharma aims to enhance treatment options for both men's and women's health by developing innovative therapies that address unmet medical needs in gynecological conditions, such as endometriosis and polycystic ovarian syndrome.

Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.

Ncardia is a biotechnology company focused on expediting the drug discovery and development process. The company leverages human induced pluripotent stem cell (hiPSC) technology to create predictive human cellular assay systems, which are used for safety and efficacy testing of drug candidates. Additionally, Ncardia enhances cardiovascular and neural drug screening, providing researchers and drug discovery companies with tools to better understand human disease biology. This approach aims to accelerate the overall drug discovery process, facilitating the development of safer and more effective therapeutic options.

OMEICOS Therapeutics GmbH is a Berlin-based company founded in 2013 that specializes in developing novel therapeutics for cardiovascular diseases and other health conditions. The company focuses on small molecule therapies derived from natural metabolites of omega-3 fatty acids, which exhibit a unique mode of action. These substances activate an endogenous cardio-protective signaling pathway, providing both anti-arrhythmic effects and curative benefits by stabilizing heart rhythm and preventing electrical and structural remodeling of the heart. In addition to cardiovascular applications, OMEICOS also explores treatments for inflammatory and ophthalmic diseases, aiming to deliver safe and effective therapeutic options for various medical indications.

Exact Imaging specializes in high-resolution micro-ultrasound systems aimed at improving real-time imaging and guided biopsies in the urological sector, particularly for prostate cancer. The company's flagship product, the ExactVu system, operates at 29 MHz, providing exceptional resolution that allows for the visualization and targeting of suspicious regions. In addition to enabling precise systematic biopsies, Exact Imaging offers the FusionVu application, which integrates micro-ultrasound with MRI to enhance prostate imaging and biopsy accuracy. Founded in 2003 and headquartered in Markham, Canada, the company was previously known as Imagistx, Inc. before rebranding in 2015.

Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

Ogeda SA is a clinical-stage drug discovery company based in Gosselies, Belgium, that focuses on inventing and developing small molecule drugs that target G-Protein Coupled Receptors (GPCRs). The company's lead product, fezolinetant, is currently in Phase II clinical development for treating women's health disorders. In addition to fezolinetant, Ogeda is developing other small molecules aimed at addressing various therapeutic areas, including inflammatory and autoimmune diseases. Founded in 1994 and formerly known as Euroscreen, Ogeda operates additional facilities in Brussels, Belgium, and Paris, France. The company is a subsidiary of Astellas Pharma Inc. and is supported by prominent investors in the biotechnology sector.

Apitope is a biotechnology company dedicated to the discovery and development of disease-modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves' disease, and uveitis. The company specializes in creating antigen-specific therapeutic peptides that directly target the underlying causes of these conditions. Apitope's innovative approach aims to provide effective treatments that enhance patients' quality of life while minimizing the risk of secondary infections and complications. The company's first product candidate is licensed to Merck Serono, and it continues to advance its remaining portfolio of product candidates developed through its proprietary platform technology.

OMEICOS Therapeutics GmbH is a Berlin-based company founded in 2013 that specializes in developing novel therapeutics for cardiovascular diseases and other health conditions. The company focuses on small molecule therapies derived from natural metabolites of omega-3 fatty acids, which exhibit a unique mode of action. These substances activate an endogenous cardio-protective signaling pathway, providing both anti-arrhythmic effects and curative benefits by stabilizing heart rhythm and preventing electrical and structural remodeling of the heart. In addition to cardiovascular applications, OMEICOS also explores treatments for inflammatory and ophthalmic diseases, aiming to deliver safe and effective therapeutic options for various medical indications.

Genkyotex SA is a biopharmaceutical company focused on developing innovative oral small molecule therapies that selectively inhibit NOX enzymes involved in various disease processes, including fibrosis, inflammation, pain, cancer, and neurodegeneration. Its lead candidate, GKT831, targets NOX1 and NOX4 and is currently undergoing Phase II clinical trials for primary biliary cholangitis and type 1 diabetes-related kidney disease. Additionally, Genkyotex is advancing a preclinical candidate, GKT771, which inhibits NOX1 and aims to address pain processing and inflammation. The company also holds a license agreement with the Serum Institute of India for GTL003, an antigen intended for developing combination vaccines against infectious diseases. Established in 2006 and headquartered in Labège, France, Genkyotex is committed to improving treatment options for chronic diseases through its novel therapeutic approaches.

Humedics GmbH, founded in 2009 and based in Berlin, Germany, specializes in the development of a breath analysis device designed to assess liver function in patients suffering from liver failure. The company's key product, the LiMAx test, is a diagnostic system that includes a medical device, breath masks, and a diagnostic drug, enabling clinicians to quantitatively evaluate individual liver function. This technology supports various applications, such as assessing liver function before and after transplantation, planning liver surgeries, and evaluating conditions like liver cirrhosis. By providing rapid and precise measurements at the bedside, LiMAx facilitates informed decision-making for tailored medical treatments, thereby enhancing patient outcomes. The company has successfully used its technology with thousands of patients and is focused on expanding its global operations.

Ncardia is a biotechnology company focused on expediting the drug discovery and development process. The company leverages human induced pluripotent stem cell (hiPSC) technology to create predictive human cellular assay systems, which are used for safety and efficacy testing of drug candidates. Additionally, Ncardia enhances cardiovascular and neural drug screening, providing researchers and drug discovery companies with tools to better understand human disease biology. This approach aims to accelerate the overall drug discovery process, facilitating the development of safer and more effective therapeutic options.

Trod Medical S.A. is a medical device manufacturer founded in 2006, with headquarters in Leuven, Belgium, and the Tampa Bay area, USA. The company specializes in innovative ablation technologies, particularly in developing radiofrequency (RF) ablation devices. One of its key products, the EncageTM, is a percutaneous RF device designed to precisely ablate soft tissues, minimizing collateral damage during procedures. This technology is particularly significant in the treatment of prostate cancer, a prevalent condition with approximately 240,000 new cases diagnosed annually in the United States. Traditional treatments often lead to severe side effects, such as erectile dysfunction and urinary incontinence, highlighting the importance of Trod Medical's advancements. The company's devices enable healthcare providers to perform endoscopic surgeries with predictable ablation volumes and reduced tissue damage, aiming to improve patient outcomes in a critical area of medical care.

Complix is a biopharmaceutical company dedicated to the discovery and development of Alphabodies™, a new class of therapeutics designed to target challenging disease targets. These Alphabodies™ exhibit high affinity for a variety of disease targets, particularly those that are difficult to access with traditional antibodies or other protein-based therapies. The unique stability and versatility of Alphabodies™ allow for alternative non-injectable delivery methods, enhancing their potential in therapeutic applications. The company's pipeline focuses on intracellular targets significant in cancer, autoimmunity, and viral diseases, aiming to combine the effectiveness of biologics with the cell-penetrating capabilities and stability characteristic of small molecules.

FF Pharma is a biopharmaceutical company focused on developing an anti-CD40 monoclonal antibody therapy aimed at treating chronic inflammatory diseases, including primary biliary cirrhosis and Crohn’s disease. The therapy acts as a negative allosteric modulator of the CD40 pathway, serving as a reversible switch for B cell activation. By inhibiting immune responses, this innovative treatment approach addresses conditions characterized by abnormal immune reactions, such as autoantibody production and chronic inflammation. Through its targeted therapy, FF Pharma aims to provide effective solutions for patients suffering from these challenging autoimmune diseases.

Ogeda SA is a clinical-stage drug discovery company based in Gosselies, Belgium, that focuses on inventing and developing small molecule drugs that target G-Protein Coupled Receptors (GPCRs). The company's lead product, fezolinetant, is currently in Phase II clinical development for treating women's health disorders. In addition to fezolinetant, Ogeda is developing other small molecules aimed at addressing various therapeutic areas, including inflammatory and autoimmune diseases. Founded in 1994 and formerly known as Euroscreen, Ogeda operates additional facilities in Brussels, Belgium, and Paris, France. The company is a subsidiary of Astellas Pharma Inc. and is supported by prominent investors in the biotechnology sector.

Genkyotex SA is a biopharmaceutical company focused on developing innovative oral small molecule therapies that selectively inhibit NOX enzymes involved in various disease processes, including fibrosis, inflammation, pain, cancer, and neurodegeneration. Its lead candidate, GKT831, targets NOX1 and NOX4 and is currently undergoing Phase II clinical trials for primary biliary cholangitis and type 1 diabetes-related kidney disease. Additionally, Genkyotex is advancing a preclinical candidate, GKT771, which inhibits NOX1 and aims to address pain processing and inflammation. The company also holds a license agreement with the Serum Institute of India for GTL003, an antigen intended for developing combination vaccines against infectious diseases. Established in 2006 and headquartered in Labège, France, Genkyotex is committed to improving treatment options for chronic diseases through its novel therapeutic approaches.

Trinean is a Belgium-based technology provider that specializes in micro-volume molecular spectroscopy. Founded in 2006 as a spin-out from Ghent University and Imec Leuven, the company develops UV/VIS spectrometers tailored for biomolecule quantification. Its products, the DropSense™16 and DropSense™96, can analyze up to 16 and 96 samples, respectively, utilizing microfluidic chips for standardized sample analysis. These instruments are designed to enhance data interpretation and facilitate laboratory automation, making them valuable tools for biologics researchers. Trinean combines its advanced analytical hardware with a comprehensive software toolbox to optimize the performance of its spectrometers.

Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. Amakem's product pipeline is based on its unique ‘Localized Drug Action' platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.

ProFibrix B.V. is a biotech company founded in 2004 that specializes in the development and marketing of products for the hemostasis and regenerative medicine markets. The company’s primary product, Fibrocaps, is a dry powder topical hemostat and tissue sealant made from a combination of fibrinogen and thrombin, aimed at stopping acute and severe bleeding during surgical procedures or following traumatic injuries. ProFibrix also provides a sterilized single-use delivery device designed to apply Fibrocaps directly to the target tissue, minimizing disruption to the wound. The company’s products leverage human fibrinogen, a natural blood protein, to enhance hemostasis, blood clotting, and tissue repair.

Genkyotex SA is a biopharmaceutical company focused on developing innovative oral small molecule therapies that selectively inhibit NOX enzymes involved in various disease processes, including fibrosis, inflammation, pain, cancer, and neurodegeneration. Its lead candidate, GKT831, targets NOX1 and NOX4 and is currently undergoing Phase II clinical trials for primary biliary cholangitis and type 1 diabetes-related kidney disease. Additionally, Genkyotex is advancing a preclinical candidate, GKT771, which inhibits NOX1 and aims to address pain processing and inflammation. The company also holds a license agreement with the Serum Institute of India for GTL003, an antigen intended for developing combination vaccines against infectious diseases. Established in 2006 and headquartered in Labège, France, Genkyotex is committed to improving treatment options for chronic diseases through its novel therapeutic approaches.

Activaero GmbH is a drug delivery company focused on the research, development, manufacture, and marketing of controlled breathing technologies for inhaled therapeutic agents. Based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero offers a range of innovative products, including AKITA, a controlled breathing device equipped with smart card technology, and Watchhaler, designed specifically for children requiring inhaled medication. The company's technologies aim to ensure efficient and safe drug deposition in the lungs, addressing severe respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and idiopathic pulmonary fibrosis. Activaero also provides AKITA² for clinical trial settings and LimiX, a flow limitation valve that regulates flow rates. Additionally, the company offers measurement and diagnostic technologies for laboratory use and contract development services for clinical trials. Its products are marketed through a network of distributors. Founded in 2004, Activaero is dedicated to improving therapy outcomes for patients with lung diseases.

Complix is a biopharmaceutical company dedicated to the discovery and development of Alphabodies™, a new class of therapeutics designed to target challenging disease targets. These Alphabodies™ exhibit high affinity for a variety of disease targets, particularly those that are difficult to access with traditional antibodies or other protein-based therapies. The unique stability and versatility of Alphabodies™ allow for alternative non-injectable delivery methods, enhancing their potential in therapeutic applications. The company's pipeline focuses on intracellular targets significant in cancer, autoimmunity, and viral diseases, aiming to combine the effectiveness of biologics with the cell-penetrating capabilities and stability characteristic of small molecules.

Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

Activaero GmbH is a drug delivery company focused on the research, development, manufacture, and marketing of controlled breathing technologies for inhaled therapeutic agents. Based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero offers a range of innovative products, including AKITA, a controlled breathing device equipped with smart card technology, and Watchhaler, designed specifically for children requiring inhaled medication. The company's technologies aim to ensure efficient and safe drug deposition in the lungs, addressing severe respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and idiopathic pulmonary fibrosis. Activaero also provides AKITA² for clinical trial settings and LimiX, a flow limitation valve that regulates flow rates. Additionally, the company offers measurement and diagnostic technologies for laboratory use and contract development services for clinical trials. Its products are marketed through a network of distributors. Founded in 2004, Activaero is dedicated to improving therapy outcomes for patients with lung diseases.

Apitope is a biotechnology company dedicated to the discovery and development of disease-modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves' disease, and uveitis. The company specializes in creating antigen-specific therapeutic peptides that directly target the underlying causes of these conditions. Apitope's innovative approach aims to provide effective treatments that enhance patients' quality of life while minimizing the risk of secondary infections and complications. The company's first product candidate is licensed to Merck Serono, and it continues to advance its remaining portfolio of product candidates developed through its proprietary platform technology.

Trinean is a Belgium-based technology provider that specializes in micro-volume molecular spectroscopy. Founded in 2006 as a spin-out from Ghent University and Imec Leuven, the company develops UV/VIS spectrometers tailored for biomolecule quantification. Its products, the DropSense™16 and DropSense™96, can analyze up to 16 and 96 samples, respectively, utilizing microfluidic chips for standardized sample analysis. These instruments are designed to enhance data interpretation and facilitate laboratory automation, making them valuable tools for biologics researchers. Trinean combines its advanced analytical hardware with a comprehensive software toolbox to optimize the performance of its spectrometers.

Genomic Vision is a biotechnology company that specializes in molecular diagnostics and technology. It utilizes a proprietary technique known as Molecular Combing, which enables the detection of single DNA molecules. The company is focused on developing and commercializing innovative genetic tests and research tools aimed at improving DNA analysis and genetic testing in areas such as cancer, rare inherited disorders, and pharmacogenomics. By combining advanced technology with biomarker discovery, Genomic Vision aims to enhance the capabilities of researchers and healthcare professionals in the life sciences sector.